Breton Hill Capital Ltd. bought a new stake in Theralase Technologies Inc. (NASDAQ:TLT) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 4,000 shares of the company’s stock, valued at approximately $499,000.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Almanack Investment Partners LLC. raised its stake in Theralase Technologies by 1.9% during the 2nd quarter. Almanack Investment Partners LLC. now owns 1,321 shares of the company’s stock valued at $165,000 after acquiring an additional 25 shares during the last quarter. CI Global Investments Inc. purchased a new stake in Theralase Technologies during the 2nd quarter valued at approximately $167,000. IndexIQ Advisors LLC raised its stake in Theralase Technologies by 42.1% during the 2nd quarter. IndexIQ Advisors LLC now owns 1,360 shares of the company’s stock valued at $170,000 after acquiring an additional 403 shares during the last quarter. FNY Partners Fund LP raised its stake in Theralase Technologies by 14,430.0% during the 2nd quarter. FNY Partners Fund LP now owns 1,433 shares of the company’s stock valued at $179,000 after acquiring an additional 1,443 shares during the last quarter. Finally, Advisors Preferred LLC purchased a new stake in Theralase Technologies during the 2nd quarter valued at approximately $199,000.
ILLEGAL ACTIVITY NOTICE: “Breton Hill Capital Ltd. Buys Shares of 4,000 Theralase Technologies Inc. (TLT)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/12/breton-hill-capital-ltd-buys-shares-of-4000-theralase-technologies-inc-tlt.html.
Theralase Technologies Inc. (NASDAQ TLT) traded down C$1.90 on Friday, reaching C$124.10. The company’s stock had a trading volume of 11,980,000 shares, compared to its average volume of 7,470,000. Theralase Technologies Inc. has a 12-month low of C$116.49 and a 12-month high of C$129.57.
The business also recently disclosed a monthly dividend, which was paid on Tuesday, November 7th. Shareholders of record on Thursday, November 2nd were paid a dividend of $0.2631 per share. The ex-dividend date of this dividend was Wednesday, November 1st. This is an increase from Theralase Technologies’s previous monthly dividend of $0.25. This represents a $3.16 annualized dividend and a yield of 2.54%.
Theralase Technologies Company Profile
iShares 20+ Year Treasury Bond ETF (the Fund) is an exchange-traded fund. The Fund seeks to track the investment results of an index composed of United States Treasury bonds with remaining maturities greater than 20 years. The Fund seeks to track the investment results of the Barclays U.S. 20+ Year Treasury Bond Index (the Underlying Index), which measures the performance of public obligations of the United States Treasury that have a remaining maturity of 20 or more years.
Want to see what other hedge funds are holding TLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theralase Technologies Inc. (NASDAQ:TLT).
Receive News & Ratings for Theralase Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.